Non-muscle-invasive bladder cancer (NMIBC), the most prevalent type of bladder cancer, accounts for ~75% of bladder cancer diagnoses. This disease has a 50% risk of recurrence and 20% risk of progression within 5 years, despite the use of intravesical adjuvant treatments (such as BCG or mitomycin C) that are recommended by clinical guidelines. Intravesical device-assisted therapies, such as radiofrequency-induced thermochemotherapeutic effect (RITE), conductive hyperthermic chemotherapy, and electromotive drug administration (EMDA), have shown promising efficacy. These device-assisted treatments are an attractive alternative to BCG, as issues with supply have been a problem in some countries. RITE might be an effective treatment option for some patients who have experienced BCG failure and are not candidates for radical cystectomy. Data from trials using EMDA suggest that it is effective in high-risk disease but requires further validation, and results of randomized trials are eagerly awaited for conductive hyperthermic chemotherapy. Considerable heterogeneity in patient cohorts, treatment sessions, use of maintenance regimens, and single-arm study design makes it difficult to draw solid conclusions, although randomized controlled trials have been reported for RITE and EMDA.

非肌肉浸润性膀胱癌（NMIBC）是最普遍的膀胱癌类型，约占诊断的膀胱癌的75％。尽管临床指南建议使用膀胱内辅助治疗（例如BCG或丝裂霉素C），但该病在5年内复发风险为50％，进展风险为20％。腔内设备辅助疗法，例如射频诱导的热化学疗法效果（RITE），传导性高温化学疗法和电动药物管理（EMDA），已显示出令人鼓舞的疗效。这些设备辅助治疗是BCG的有吸引力的替代方法，因为在某些国家中供应问题一直是一个问题。对于某些经历过BCG衰竭且不适合行根治性膀胱切除术的患者，RITE可能是一种有效的治疗选择。使用EMDA的试验数据表明，它在高危疾病中有效，但需要进一步验证，急切地等待进行传导性高温化学疗法的随机试验结果。尽管已有关于RITE和EMDA的随机对照试验报道，但在患者队列，治疗方案，维持治疗方案的使用和单臂研究设计方面存在很大的异质性，因此很难得出可靠的结论。